ACADIA Pharmaceuticals trades as part of the biotechnology industry and is in the healthcare sector. The company CEO is Stephen R. Davis. ACADIA Pharmaceuticals Inc is a biotechnology company which develops and commercializes biopharmaceutical products to address central nervous system disorders. It aims to discover small molecule drugs to address Parkinson’s, Alzheimer’s and schizophrenia.
Previous Intraday Performance:
The ACAD shares had a previous change of 2.45% which opened at 25.45 and closed at 25.96. It moved to an intraday high of 26.10 and a low of 25.45.
SeekingAlpha: 3 Gene Therapy Stocks For A Biotech Portfolio
Historical Performance:
Over the last five trading days, ACAD shares returned 7.14% and in the past 30 trading days it returned 1.09%. Over three months, it changed 13.76%. In one year it has changed 46.92% and within that year its 52 week high was 28.67 and its 52 week low was 12.77. ACAD stock is 103.29% above its 52 week low.
Our calculations result in a 200 day moving average of 21.04 and a 50 day moving average of 25.81. Right now, ACAD stock is trading 23.39% above its 200 day moving average.
SeekingAlpha: 3 Gene Therapy Stocks For A Biotech Portfolio
Liquidity:
The company has a market cap of $3.7b with 143.9m shares outstanding and a float of 143.3m shares. Trading volume was 924,541 shares and has experienced an average volume of 1,124,063 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is good.
Earnings:
The last annual reported EPS for ACADIA Pharmaceuticals was -1.95 which ended on 31st of December 2018. Based on 5 analyst estimates, the consensus EPS for the next quarter is -0.54.
Below was the last reported quarterly diluted earnings per share:
| 1st | Qtr 2019 | -0.59 |
|---|---|---|
| 4th | Qtr 2018 | -0.50 |
| 3rd | Qtr 2018 | -0.50 |
| 2nd | Qtr 2018 | -0.51 |
| 1st | Qtr 2018 | -0.44 |
Base on our calculations, the intrinsic value per share is 44.76, which means it might be undervalued and has a margin of safety of 42.00%.
The long-term trend of the EPS is an important number as it indicates the present value of ACADIA Pharmaceuticals; the EPS growth rate, as it is usually called, is typically displayed as a percentage, which at this time is hard to estimate, but revenue growth has been 41.20% over the last twelve months.
Indicators Also to Watch:
The beta was calculated to be 3.02.
Business Wire: National Cardiogenic Shock Initiative (NCSI) with Impella Best Practices Demonstrates 72% Survival with 98% Native Heart Recovery
Fundamental Numbers:
Based on last reported financials, the company’s return on equity is -79.43%, return on assets is -67.30%, price-to-sales is 15.33 and price-to-book is 8.95.
Company Score Card:
Results are out of six:
5 : Growth Expectations Result
5 : Financial Safety Result
0 : Past Performance Result
2 : Valuation Result
0 : Dividend Safety Result
3 : Overall Result
Related Tags: ACAD, ACADIA Pharmaceuticals, Biotechnology, Healthcare
